### Table of Contents

**Highlights of This Issue** 2503

**SPECIAL FEATURES**

- **CCR Translations**
  - 2505 Minimal Residual Disease in Breast Cancer: In Blood Veritas
    Giulia Siravegna and Alberto Bardelli
    *See related article, p. 2643*

- **Molecular Pathways**
  - 2508 Molecular Pathways: Preclinical Models and Clinical Trials with Metformin in Breast Cancer
    Alastair M. Thompson
  - 2516 Molecular Pathways: Adaptive Kinome Reprogramming in Response to Targeted Inhibition of the BRAF–MEK–ERK Pathway in Cancer
    Gary L. Johnson, Timothy J. Stuhlmiller, Steven P. Angus, Jon S. Zawistowski, and Lee M. Graves

- **CCR Focus**
  - 2524 The Language of Pharmacodynamics
    Susan E. Bates
  - 2525 Pharmacologic Biomarkers in the Development of Stratified Cancer Medicine
    William Douglas Figg and David R. Newell
  - 2530 Using Pharmacogene Polymorphism Panels to Detect Germline Pharmacodynamic Markers in Oncology
    Daniel L. Hertz and Howard L. McLeod
  - 2541 Genome-Wide Association Study: A Useful Tool to Identify Common Genetic Variants Associated with Drug Toxicity and Efficacy in Cancer Pharmacogenomics
    Siew-Kee Low, Atsushi Takahashi, Taisei Mushiroda, and Michiaki Kubo
  - 2553 Circulating Tumor Cells: A Multifunctional Biomarker
    Timothy A. Yap, David Lorente, Aurelius Omlin, David Olmos, and Johann S. de Bono

**HUMAN CANCER BIOLOGY**

- 2569 In Vivo Imaging as a Pharmacodynamic Marker
  Astrid A.M. van der Veldt and Adriaan A. Lamertsma

- 2578 Implementation of Validated Pharmacodynamic Assays in Multiple Laboratories: Challenges, Successes, and Limitations
  Robert Kinders, Kate Ferry-Galow, Lihua Wang, Apurva K. Srivastava, Jiuping (Jay) Ji, and Ralph E. Parchment

- 2587 Pharmacodynamic Biomarkers: Falling Short of the Mark?
  Justin F. Gainor, Dan L. Longo, and Bruce A. Chabner

**May 15, 2014 • Volume 20 • Number 10**

**Clinical Cancer Research**

**Table of Contents**

- **CCR Translations**
  - 2505 Minimal Residual Disease in Breast Cancer: In Blood Veritas
    Giulia Siravegna and Alberto Bardelli
    *See related article, p. 2643*

- **Molecular Pathways**
  - 2508 Molecular Pathways: Preclinical Models and Clinical Trials with Metformin in Breast Cancer
    Alastair M. Thompson
  - 2516 Molecular Pathways: Adaptive Kinome Reprogramming in Response to Targeted Inhibition of the BRAF–MEK–ERK Pathway in Cancer
    Gary L. Johnson, Timothy J. Stuhlmiller, Steven P. Angus, Jon S. Zawistowski, and Lee M. Graves

- **CCR Focus**
  - 2524 The Language of Pharmacodynamics
    Susan E. Bates
  - 2525 Pharmacologic Biomarkers in the Development of Stratified Cancer Medicine
    William Douglas Figg and David R. Newell
  - 2530 Using Pharmacogene Polymorphism Panels to Detect Germline Pharmacodynamic Markers in Oncology
    Daniel L. Hertz and Howard L. McLeod
  - 2541 Genome-Wide Association Study: A Useful Tool to Identify Common Genetic Variants Associated with Drug Toxicity and Efficacy in Cancer Pharmacogenomics
    Siew-Kee Low, Atsushi Takahashi, Taisei Mushiroda, and Michiaki Kubo
  - 2553 Circulating Tumor Cells: A Multifunctional Biomarker
    Timothy A. Yap, David Lorente, Aurelius Omlin, David Olmos, and Johann S. de Bono

**HUMAN CANCER BIOLOGY**

- 2569 In Vivo Imaging as a Pharmacodynamic Marker
  Astrid A.M. van der Veldt and Adriaan A. Lamertsma

- 2578 Implementation of Validated Pharmacodynamic Assays in Multiple Laboratories: Challenges, Successes, and Limitations
  Robert Kinders, Kate Ferry-Galow, Lihua Wang, Apurva K. Srivastava, Jiuping (Jay) Ji, and Ralph E. Parchment

- 2587 Pharmacodynamic Biomarkers: Falling Short of the Mark?
  Justin F. Gainor, Dan L. Longo, and Bruce A. Chabner
Table of Contents

2643 Detection of Cancer DNA in Plasma of Patients with Early-Stage Breast Cancer
See related article, p. 2505

CANCER THERAPY: PRECLINICAL

2651 Id1-Induced IGF-II and Its Autocrine/Endocrine Promotion of Esophageal Cancer Progression and Chemoresistance—Implications for IGF-II and IGF-IR–Targeted Therapy
Bin Li, Sai Wah Tsao, Kwok Wah Chan, Dale L. Ludwig, Ruslan Novosyadlyy, Yuk Yin Li, Qing Yu He, and Annie L.M. Cheung

2663 COX-2–Independent Effects of Celecoxib Sensitize Lymphoma B Cells to TRAIL-Mediated Apoptosis
Anne-Sophie Gallouet, Marion Travert, Laurence Bresson-Bepoldin, Fabien Guilloton, Céline Pangault, Sylvie Caulot-Maugendre, Thierry Lamy, Karin Tarte, and Thierry Guillaudeux

2674 Selective JAK2 Inhibition Specifically Decreases Hodgkin Lymphoma and Mediastinal Large B-cell Lymphoma Growth In Vitro and In Vivo
Yansheng Hao, Bjorn Chapuy, Stefano Monti, Heather H. Sun, Scott J. Rodig, and Margaret A. Shipp

2684 Recognition and Killing of Autologous, Primary Glioblastoma Tumor Cells by Human Cytomegalovirus pp65-Specific Cytotoxic T Cells
Smita K. Nair, Gabriel De Leon, David Boczkowski, Robert Schmittling, Weihua Xie, Janet Staats, Rebecca Liu, Laura A. Johnson, Kent Weinhold, Gary E. Archer, John H. Sampson, and Duane A. Mitchell

2695 Anti-VEGF Antibodies Mitigate the Development of Radiation Necrosis in Mouse Brain

2703 ABCB1, ABCG2, and PTEN Determine the Response of Glioblastoma to Temozolomide and ABT-888 Therapy
Fan Lin, Mark C. de Gooijer, Eloy Moreno Roig, Levi C.M. Buil, Susan M. Christner, Jan H. Beumer, Thomas Würdinger, Jos H. Beijnen, and Olaf van Tellingen

2714 Metformin Sensitizes EGFR-TKI–Resistant Human Lung Cancer Cells In Vitro and In Vivo through Inhibition of IL-6 Signaling and EMT Reversal
Li Li, Rui Han, HuaiLiang Xiao, Caifu Lin, Yubo Wang, Hao Liu, Kumlun Li, Hengyi Chen, Fenfen Sun, Zhenzhou Yang, Jianxin Jiang, and Yong He

2727 Profound Prevention of Experimental Brain Metastases of Breast Cancer by Temozolomide in an MGMT-Dependent Manner
Diane Palmieri, Renata Duchnowska, Stephan Woditschka, Emily Hua, Yongzhen Qian, Wojciech Biernat, Katarzyna Soniska-Mielcarek, Brunilde Grill, Andreas M. Stark, Stephen M. Hewitt, David J. Liewehr, Seth M. Steinberg, Jaoek Jaksem, and Patricia S. Steeg

2740 Biologic Effects of Platelet-Derived Growth Factor Receptor α Blockade in Uterine Cancer
Ju-Won Roh, Jie Huang, Wei Hu, XiaoYun Yang, Nicholas B. Jennings, Vasudha Sehgal, Bo Hwa Sohn, Hee Dong Han, Sun Joo Lee, Duangmani Thanapprapasr, Justin Bottsford-Miller, Behrouz Zand, Heather J. Dalton, Rebecca A. Previs, Ashley N. Davis, Koji Matsuo, Ju-Seog Lee, Prahlad Ram, Robert L. Coleman, and Anil K. Sood

IMAGING, DIAGNOSIS, PROGNOSIS

2751 Repeatability of Quantitative FDG-PET/CT and Contrast-Enhanced CT in Recurrent Ovarian Carcinoma: Test–Retest Measurements for Tumor FDG Uptake, Diameter, and Volume
Andrea G. Rockall, Norbert Avril, Raymond Lam, Robert Iannone, P. David Mozley, Christine Parkinson, Donald Bergstrom, Evis Sala, Shah-Jalal Sarker, Iain A. McNeish, and James D. Brenton
A Signature Predicting Poor Prognosis in Gastric and Ovarian Cancer Represents a Coordinated Macrophage and Stromal Response
Rita A. Busuttil, Joshy George, Richard W. Tothill, Kylie Ioculano, Adam Kowalczyk, Catherine Mitchell, Stephen Lade, Patrick Tan, Izhak Haviv, and Alex Boussioutas

In Situ Tumor PD-L1 mRNA Expression Is Associated with Increased TILs and Better Outcome in Breast Carcinomas
Kurt A. Schalper, Vamsidhar Velcheti, Daniel Carvajal, Hallie Wimberly, Jason Brown, Lajos Pusztai, and David L. Rimm

Population Pharmacokinetics of Bevacizumab in Children with Osteosarcoma: Implications for Dosing

Quantitative Measurements of Tumoral p95HER2 Protein Expression in Metastatic Breast Cancer Patients Treated with Trastuzumab: Independent Validation of the p95HER2 Clinical Cutoff
Renata Duchnowska, Jeff Sperinde, Ahmed Chenna, Mojgan Haddad, Agnes Paquet, Yolanda Lie, Jodi M. Weidler, Weidong Huang, John Winslow, Tomasz Jankowski, Bogumila Czartoryska-Arulkowicz, Piotr J. Wysocki, Małgorzata Foszczyńska-Kłodska, Barbara Radecka, Maria M. Litwiniuk, Jolanta Żok, Michał Wiśniewski, Dorota Zuziak, Wojciech Biernat, and Jacek Jassem

Table of Contents

2761 A Signature Predicting Poor Prognosis in Gastric and Ovarian Cancer Represents a Coordinated Macrophage and Stromal Response
2773 In Situ Tumor PD-L1 mRNA Expression Is Associated with Increased TILs and Better Outcome in Breast Carcinomas
2783 Population Pharmacokinetics of Bevacizumab in Children with Osteosarcoma: Implications for Dosing
2793 A Pharmacodynamic/Pharmacokinetic Study of Ficlatuzumab in Patients with Advanced Solid Tumors and Liver Metastases
2805 Quantitative Measurements of Tumoral p95HER2 Protein Expression in Metastatic Breast Cancer Patients Treated with Trastuzumab: Independent Validation of the p95HER2 Clinical Cutoff

CANCER THERAPY: CLINICAL

PREDICTIVE BIOMARKERS AND PERSONALIZED MEDICINE

ABOUT THE COVER

The cover shows a brain section from a mouse injected with a brain seeking variant of the human breast cancer cell line MDA-MB-231. Immunohistochemical staining indicates a lack of MGMT expression in the tumor cells. Tissue was stained with anti-MGMT antibody and counterstained with hematoxylin and eosin. For details, see the article by Palmieri and colleagues on page 2727 of this issue.